Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3500
Buy Report

Published: March 31, 2022 Report Code: GMDGDHC22029TDB-ST

Select Item

Tyrosine Protein Kinase SYK pipeline market report provides comprehensive information on the Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

Key MoA in the Tyrosine Protein Kinase SYK Pipeline Market

The key MoA in the Tyrosine Protein Kinase SYK pipeline market is Tyrosine Protein Kinase SYK Inhibitor.

Key RoA in the Tyrosine Protein Kinase SYK Pipeline Market

The key RoA in the Tyrosine Protein Kinase SYK pipeline market are oral, ophthalmic, topical, inhalational, and nasal. Oral has the highest pipeline products.

Tyrosine Protein Kinase SYK Pipeline Market, by RoA

Tyrosine Protein Kinase SYK Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Type in the Tyrosine Protein Kinase SYK Pipeline Market

The key molecule types in the Tyrosine Protein Kinase SYK pipeline market is small molecule.

Key Companies in the Tyrosine Protein Kinase SYK Pipeline Market

The key companies in the Tyrosine Protein Kinase SYK pipeline market are Alexion Pharmaceuticals, Aptose Biosciences Inc, Archer Pharmaceuticals Inc, Asana BioSciences LLC, Beijing Hanmi Pharmaceutical Co Ltd, Calithera Biosciences Inc, and Clevexel Pharma SA. Alexion Pharmaceuticals has the highest pipeline products.

Tyrosine Protein Kinase SYK Pipeline Market, by Companies

Tyrosine Protein Kinase SYK Pipeline Market, by Companies

To know more about companies, download a free report sample

Market report overview

Key MoA Tyrosine Protein Kinase SYK Inhibitor
Key RoA Oral, Ophthalmic, Topical, Inhalational, and Nasal
Key Molecule Types Small Molecule
Key Companies Alexion Pharmaceuticals, Aptose Biosciences Inc, Archer Pharmaceuticals Inc, Asana BioSciences LLC, Beijing Hanmi Pharmaceutical Co Ltd, Calithera Biosciences Inc, and Clevexel Pharma SA

Scope

  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)
  • The report reviews Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

AB Science SA
Alexion Pharmaceuticals Inc
Aptose Biosciences Inc
Archer Pharmaceuticals Inc
Asana BioSciences LLC
Beijing Hanmi Pharmaceutical Co Ltd
Calithera Biosciences Inc
Clevexel Pharma SA
CSPC Pharmaceutical Group Ltd
Genosco Inc
GlaxoSmithKline Plc
Hutchison MediPharma Ltd
IACTA Pharmaceuticals Inc
Japan Tobacco Inc
Kronos Bio Inc
Levolta Pharmaceuticals Inc
Nano Biotherapeutics Inc
Origenis GmbH
Pulmatrix Inc
Rigel Pharmaceuticals Inc
Taiho Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC

2.7.10.2) – Overview

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC

2.7.10.2) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC

2.7.10.2) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC

2.7.10.2) – Companies Involved in Therapeutics Development

AB Science SA

Alexion Pharmaceuticals Inc

Aptose Biosciences Inc

Archer Pharmaceuticals Inc

Asana BioSciences LLC

Beijing Hanmi Pharmaceutical Co Ltd

Calithera Biosciences Inc

Clevexel Pharma SA

CSPC Pharmaceutical Group Ltd

Genosco Inc

GlaxoSmithKline Plc

Hutchison MediPharma Ltd

IACTA Pharmaceuticals Inc

Japan Tobacco Inc

Kronos Bio Inc

Levolta Pharmaceuticals Inc

Nano Biotherapeutics Inc

Origenis GmbH

Pulmatrix Inc

Rigel Pharmaceuticals Inc

Taiho Pharmaceutical Co Ltd

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC

2.7.10.2) – Drug Profiles

AB-8779 – Drug Profile

Product Description

Mechanism Of Action

cerdulatinib – Drug Profile

Product Description

Mechanism Of Action

History of Events

cevidoplenib – Drug Profile

Product Description

Mechanism Of Action

History of Events

CVXL-0074 – Drug Profile

Product Description

Mechanism Of Action

History of Events

entospletinib – Drug Profile

Product Description

Mechanism Of Action

History of Events

fostamatinib disodium – Drug Profile

Product Description

Mechanism Of Action

History of Events

GNS-1653 – Drug Profile

Product Description

Mechanism Of Action

GS-492429 – Drug Profile

Product Description

Mechanism Of Action

History of Events

GSK-2646264 – Drug Profile

Product Description

Mechanism Of Action

History of Events

gusacitinib hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

HM-43239 – Drug Profile

Product Description

Mechanism Of Action

History of Events

IC-265 – Drug Profile

Product Description

Mechanism Of Action

History of Events

IC-270 – Drug Profile

Product Description

Mechanism Of Action

History of Events

JTE-852 – Drug Profile

Product Description

Mechanism Of Action

lanraplenib succinate – Drug Profile

Product Description

Mechanism Of Action

History of Events

mivavotinib citrate – Drug Profile

Product Description

Mechanism Of Action

History of Events

nilvadipine – Drug Profile

Product Description

Mechanism Of Action

History of Events

piceatannol albumin bound – Drug Profile

Product Description

Mechanism Of Action

History of Events

PRT-2761 – Drug Profile

Product Description

Mechanism Of Action

History of Events

PUR-1800 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit SYK and JAK for Rheumatoid Arthritis and Unspecified Cancer – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit SYK for Ocular Inflammation – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit H1-SYK for Unspecified Ophthalmic Diseases – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit Spleen Tyrosine Kinase for Immunology and Oncology – Drug Profile

Product Description

Mechanism Of Action

History of Events

sovleplenib – Drug Profile

Product Description

Mechanism Of Action

History of Events

SYHX-1901 – Drug Profile

Product Description

Mechanism Of Action

History of Events

TAS-05567 – Drug Profile

Product Description

Mechanism Of Action

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC

2.7.10.2) – Dormant Products

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC

2.7.10.2) – Discontinued Products

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC

2.7.10.2) – Product Development Milestones

Featured News & Press Releases

Mar 08, 2022: Rigel announces publication of data from phase 2 clinical study of fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia in the American Journal of Hematology

Jan 12, 2022: HUTCHMED receives Breakthrough Therapy designation in China for HMPL-523 for treatment of primary immune thrombocytopenia

Dec 21, 2021: Fostamatinib meets primary endpoint in phase 3 trial in Japan for treatment of chronic immune thrombocytopenia

Dec 14, 2021: HUTCHMED highlights HMPL-523 clinical data presented at the 2021 ASH Annual Meeting

Dec 13, 2021: HM43239 demonstrates durable clinical benefit in acute myeloid leukemia

Dec 06, 2021: Kronos Bio announces first patient dosed in AGILITY phase 3 clinical trial of entospletinib in patients with newly diagnosed NPM1-mutated acute myeloid leukemia

Nov 15, 2021: Rigel sharpens focus on its advanced portfolio opportunities

Nov 08, 2021: HUTCHMED highlights HMPL-523 clinical data to be presented at the 2021 ASH Annual Meeting

Oct 27, 2021: HUTCHMED initiates ESLIM-01, a phase III trial of HMPL-523 in patients with immune thrombocytopenia in China

Sep 01, 2021: Data from NIH/NHLBI-sponsored phase 2 trial of Fostamatinib in hospitalized COVID-19 patients published in clinical infectious diseases

Aug 13, 2021: Rigel Pharmaceuticals provides update on COVID-19 program

Jul 27, 2021: Kronos Bio announces FDA clearance of investigational new drug application for lanraplenib (LANRA) for treatment of patients with acute myeloid leukemia (AML)

Jul 14, 2021: New TAVALISSE data analyses to be presented at International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress

Jun 29, 2021: Fostamatinib selected for NIH ACTIV-4 COVID-19 clinical trial

Apr 22, 2021: Asana BioSciences to present additional efficacy data from chronic hand eczema Phase 2b trial of oral SYK/JAK inhibitor Gusacitinib at AAD VMX late-breaking session

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Indications, 2022 (Contd..1)

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Companies, 2022 (Contd..4)

Products under Development by Companies, 2022 (Contd..5)

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by AB Science SA, 2022

Pipeline by Alexion Pharmaceuticals Inc, 2022

Pipeline by Aptose Biosciences Inc, 2022

Pipeline by Archer Pharmaceuticals Inc, 2022

Pipeline by Asana BioSciences LLC, 2022

Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, 2022

Pipeline by Calithera Biosciences Inc, 2022

Pipeline by Clevexel Pharma SA, 2022

Pipeline by CSPC Pharmaceutical Group Ltd, 2022

Pipeline by Genosco Inc, 2022

Pipeline by GlaxoSmithKline Plc, 2022

Pipeline by Hutchison MediPharma Ltd, 2022

Pipeline by IACTA Pharmaceuticals Inc, 2022

Pipeline by Japan Tobacco Inc, 2022

Pipeline by Kronos Bio Inc, 2022

Pipeline by Levolta Pharmaceuticals Inc, 2022

Pipeline by Nano Biotherapeutics Inc, 2022

Pipeline by Origenis GmbH, 2022

Pipeline by Pulmatrix Inc, 2022

Pipeline by Rigel Pharmaceuticals Inc, 2022

Pipeline by Taiho Pharmaceutical Co Ltd, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Dormant Products, 2022 (Contd..2)

Dormant Products, 2022 (Contd..3)

Dormant Products, 2022 (Contd..4)

Dormant Products, 2022 (Contd..5)

Discontinued Products, 2022

Discontinued Products, 2022 (Contd..1)

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Frequently asked questions

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$3,500

Can be used by individual purchaser only

Most Popular
$7,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Other Diseases reports
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Pharmaceuticals
New
Generic Drugs - Physician Perspective - Thematic Intelligence
$1,495 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more